The efficacy of voriconazole in 24 ocular Fusarium infections

Infection

Volumn 41, Issue 1, 2013, Pages 15-20

  Troke, P ^a   Obenga, G ^b   Gaujoux, T ^c   Goldschmidt, P ^c   Bienvenu, A L ^d   Cornet, M ^e   Grenouillet, F ^f   Pons, D ^g   Ranque, S ^h   Sitbon, K ⁱ   Chaumeil, C ^c   Borderie, V ^c   Lortholary, O ^b,i,j  

^a Old Court ^*  (United Kingdom)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HÔTEL DIEU   (France)

^f UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^g Gabriel MontPied   (France)

^h TIMONE HOSPITAL   (France)

ⁱ INSTITUT PASTEUR   (France)

^j CNRS   (France)

more..

Author keywords

Endophthalmitis; Fusariosis; Keratitis; Ophthalmology; Voriconazole

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICONAZOLE; NATAMYCIN; POLY(HEXAMETHYLENEBIGUANIDE); VORICONAZOLE;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNGAL ENDOPHTHALMITIS; FUSARIOSIS; FUSARIUM; FUSARIUM MONILIFORME; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; HUMAN; KERATOMYCOSIS; MALE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SYSTEMIC THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; EYE INFECTIONS, FUNGAL; FUSARIOSIS; FUSARIUM; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84873718906     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0273-2     Document Type: Article

References (43)

1. Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113:1943-8.
2. Chang DC, Grant GB, O'Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953-63.
3. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695-704.
4. Tuft SJ, Tullo AB. Fungal keratitis in the United Kingdom 2003-2005. Eye. 2009;23:1308-13.
5. Rondeau N, Bourcier T, Chaumeil C, et al. Fungal keratitis at the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts: retrospective study of 19 cases. J Fr Ophtalmol. 2002;25:890-6.
6. Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. Curr Eye Res. 2010;35:953-60.
7. Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol. 2010;149:916-21.
8. Lau D, Leung L, Ferdinands M, et al. Penetration of 1 % voriconazole eye drops into human vitreous humour: a prospective, open-label study. Clin Exp Ophthalmol. 2009;37:197-200.
9. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122:42-7.
10. Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN. Aqueous and vitreous concentrations following topical administration of 1 % voriconazole in humans. Arch Ophthalmol. 2008;126:18-22.
11. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol. 2008;92:871-8.
12. Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52:648-53.
13. Prajna NV, Mascarenhas J, Krishnan T, et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol. 2010;128:672-8.
14. Arora R, Gupta D, Goyal J, Kaur R. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers. Clin Exp Ophthalmol. 2011;39:434-40.
15. Tu EY. Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin. Cornea. 2009;28:116-9.
16. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol. 2007;143:151-3.
17. Klont RR, Eggink CA, Rijs AJ, Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis. 2005;40:e110-2.
18. Cakir M, Imamoǧlu S, Cekiç O, et al. An outbreak of early-onset endophthalmitis caused by Fusarium species following cataract surgery. Curr Eye Res. 2009;34:988-95.
19. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol. 2005;140:552-4.
20. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol. 2000;84:932-3.
21. Bang S, Edell E, Eghrari AO, Gottsch JD. Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am J Ophthalmol. 2010;149:66-9.
22. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. 2006;53:121-6.
23. Tu EY, Joslin CE, Shoff ME. Successful treatment of chronic stromal Acanthamoeba keratitis with oral voriconazole monotherapy. Cornea. 2010;29:1066-8.
24. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006;46:235-43.
25. Kadikoy H, Barkmeier A, Peck B, Carvounis PE. Persistent photopsia following course of oral voriconazole. J Ocul Pharmacol Ther. 2010;26:387-8.
26. Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol. 2010;4:391-405.
27. Bullock JD. An outbreak of Fusarium keratitis associated with contact lens use in the northeastern United States. Cornea. 2008;27:973-4.
28. Gaujoux T, Borsali E, Goldschmidt P, et al. Fungal keratitis in France. Acta Ophthalmol. 2011;89:e215-6.
29. Rao SK, Lam PT, Li EY, Yuen HK, Lam DS. A case series of contact lens-associated Fusarium keratitis in Hong Kong. Cornea. 2007;26:1205-9.
30. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-31.
31. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446-50.
32. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag. 2007;3:1165-73.
33. Dupuis A, Tournier N, Le Moal G, Venisse N. Preparation and stability of voriconazole eye drop solution. Antimicrob Agents Chemother. 2009;53:798-9.
34. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005;139:135-40.
35. Oude Lashof AML, Rothova A, Sobel JD, et al. Ocular manifestations of candidemia. Clin Infect Dis. 2011;53:262-8.
36. Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology. 2009;258:84-93.
37. Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina. 2009;29:362-70.
38. Lau D, Fedinands M, Leung L, et al. Penetration of voriconazole, 1 %, eyedrops into human aqueous humor: a prospective open-label study. Arch Ophthalmol. 2008;126:343-6.
39. Galarreta DJ, Tuft SJ, Ramsay A, Dart JK. Fungal keratitis in London: microbiological and clinical evaluation. Cornea. 2007;26:1082-6.
40. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother. 2008;61:616-20.
41. Azor M, Cano J, Gené J, Guarro J. High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum. J Antimicrob Chemother. 2009;63:1152-5.
42. Azor M, Gené J, Cano J, Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother. 2007;51:1500-3.
43. Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-7.